Literature DB >> 12181419

Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity.

Robert H Tukey1, Christian P Strassburg, Peter I Mackenzie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12181419     DOI： 10.1124/mol.62.3.446

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN： 0026-895X            Impact factor:   4.436


× No keyword cloud information.
  18 in total

1.  Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer.

Authors:  Wei Tang; Yi-Ping Fu; Jonine D Figueroa; Núria Malats; Montserrat Garcia-Closas; Nilanjan Chatterjee; Manolis Kogevinas; Dalsu Baris; Michael Thun; Jennifer L Hall; Immaculata De Vivo; Demetrius Albanes; Patricia Porter-Gill; Mark P Purdue; Laurie Burdett; Luyang Liu; Amy Hutchinson; Timothy Myers; Adonina Tardón; Consol Serra; Alfredo Carrato; Reina Garcia-Closas; Josep Lloreta; Alison Johnson; Molly Schwenn; Margaret R Karagas; Alan Schned; Amanda Black; Eric J Jacobs; W Ryan Diver; Susan M Gapstur; Jarmo Virtamo; David J Hunter; Joseph F Fraumeni; Stephen J Chanock; Debra T Silverman; Nathaniel Rothman; Ludmila Prokunina-Olsson
Journal:  Hum Mol Genet       Date:  2012-01-06       Impact factor: 6.150

2.  Humanized UGT1 Mice, Regulation of UGT1A1, and the Role of the Intestinal Tract in Neonatal Hyperbilirubinemia and Breast Milk-Induced Jaundice.

Authors:  Shujuan Chen; Robert H Tukey
Journal:  Drug Metab Dispos       Date:  2018-08-09       Impact factor: 3.922

3.  Irinotecan therapy in a 12-year-old girl with recurrent brain stem glioma and without functional polymorphisms in UGT1A1 activity: case report.

Authors:  Kazuhiro Ishikawa; Yasukazu Kajita; Yoshinori Hasegawa; Yukihiro Noda; Jun Yoshida; Toshitaka Nabeshima
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

4.  Association between UGT1A1*28*28 genotype and lung cancer in the Japanese population.

Authors:  Yoshitaka Nishikawa; Masashi Kanai; Maiko Narahara; Akiko Tamon; J B Brown; Kei Taneishi; Masahiko Nakatsui; Kazuya Okamoto; Yu Uneno; Daisuke Yamaguchi; Teruko Tomono; Yukiko Mori; Shigemi Matsumoto; Yasushi Okuno; Manabu Muto
Journal:  Int J Clin Oncol       Date:  2016-11-10       Impact factor: 3.402

5.  A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation.

Authors:  Hongliang Cai; Nghia Nguyen; Vincent Peterkin; Young-Sun Yang; Kathy Hotz; Deirdre Beaton La Placa; Shujuan Chen; Robert H Tukey; Jeffrey C Stevens
Journal:  Drug Metab Dispos       Date:  2010-02-02       Impact factor: 3.922

Review 6.  Gene replacement therapy for genetic hepatocellular jaundice.

Authors:  Remco van Dijk; Ulrich Beuers; Piter J Bosma
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

7.  UGT1A1, UGT1A6 and UGT1A7 genetic analysis: repercussion for irinotecan pharmacogenetics in the São Miguel Island Population (Azores, Portugal).

Authors:  Paula R Pacheco; Maria J Brilhante; Cristina Ballart; Francesc Sigalat; Helena Polena; Rita Cabral; Claudia C Branco; Luisa Mota-Vieira
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

8.  UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.

Authors:  Christoph Schulz; Volker Heinemann; Andreas Schalhorn; Nikolas Moosmann; Thomas Zwingers; Stefan Boeck; Clemens Giessen; Hans-Joachim Stemmler
Journal:  World J Gastroenterol       Date:  2009-10-28       Impact factor: 5.742

Review 9.  PharmGKB summary: very important pharmacogene information for UGT1A1.

Authors:  Julia M Barbarino; Cyrine E Haidar; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2014-03       Impact factor: 2.089

10.  Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy.

Authors:  Jing Li; Martin H Bluth
Journal:  Pharmgenomics Pers Med       Date:  2011-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.